CL2024000834A1 - Proteína mutante de interleucina-2 y fusión de la misma - Google Patents

Proteína mutante de interleucina-2 y fusión de la misma

Info

Publication number
CL2024000834A1
CL2024000834A1 CL2024000834A CL2024000834A CL2024000834A1 CL 2024000834 A1 CL2024000834 A1 CL 2024000834A1 CL 2024000834 A CL2024000834 A CL 2024000834A CL 2024000834 A CL2024000834 A CL 2024000834A CL 2024000834 A1 CL2024000834 A1 CL 2024000834A1
Authority
CL
Chile
Prior art keywords
protein
mutant protein
dimer
fusion
immunoconjugate
Prior art date
Application number
CL2024000834A
Other languages
English (en)
Spanish (es)
Inventor
He Kaijie
Fu Fenggen
Wu Weiwei
Zhou Shuaixiang
Guan Jian
Original Assignee
Fortvita Biologics Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fortvita Biologics Singapore Pte Ltd filed Critical Fortvita Biologics Singapore Pte Ltd
Publication of CL2024000834A1 publication Critical patent/CL2024000834A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CL2024000834A 2021-09-22 2024-03-21 Proteína mutante de interleucina-2 y fusión de la misma CL2024000834A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111110032 2021-09-22

Publications (1)

Publication Number Publication Date
CL2024000834A1 true CL2024000834A1 (es) 2024-09-06

Family

ID=85720093

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000834A CL2024000834A1 (es) 2021-09-22 2024-03-21 Proteína mutante de interleucina-2 y fusión de la misma

Country Status (14)

Country Link
US (2) US20240391973A1 (enExample)
EP (1) EP4406965A4 (enExample)
JP (2) JP7864826B2 (enExample)
KR (1) KR20240082364A (enExample)
CN (1) CN118119635A (enExample)
AU (2) AU2022350407B2 (enExample)
CA (1) CA3233075A1 (enExample)
CL (1) CL2024000834A1 (enExample)
CO (1) CO2024004910A2 (enExample)
IL (1) IL311643A (enExample)
MX (1) MX2024003535A (enExample)
PE (1) PE20241994A1 (enExample)
TW (1) TWI858393B (enExample)
WO (1) WO2023045977A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105634B (zh) 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
WO2025007037A1 (en) * 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
WO2025031434A1 (zh) * 2023-08-08 2025-02-13 北京志道生物科技有限公司 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途
AU2024411090A1 (en) 2023-12-28 2026-07-16 Fortvita Biologics (Singapore) Pte. Ltd. Pd-1/il-2r bispecific antibody fusion protein, and use and usage method thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN118373896B (zh) * 2024-04-19 2025-07-29 上海科棋药业科技有限公司 抗pd-1抗体与il-2突变体的双功能融合蛋白
WO2025252212A1 (zh) * 2024-06-07 2025-12-11 福佑泰生物制药公司 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
WO2026083295A1 (en) * 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
CN121293311B (zh) * 2025-08-01 2026-07-24 合肥天港免疫药物有限公司 Il-2变体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
CN111868079B (zh) * 2017-12-27 2025-06-17 协和麒麟株式会社 Il-2变体
CN112105634B (zh) * 2018-09-21 2024-03-12 信达生物制药(苏州)有限公司 新型白介素2及其用途
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
KR20220155316A (ko) * 2020-03-19 2022-11-22 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 인터루킨-2 돌연변이 및 이의 용도
WO2021185362A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途

Also Published As

Publication number Publication date
TW202320862A (zh) 2023-06-01
US20260053898A1 (en) 2026-02-26
EP4406965A1 (en) 2024-07-31
AU2025275202A1 (en) 2026-02-19
CO2024004910A2 (es) 2024-07-08
CA3233075A1 (en) 2023-03-30
WO2023045977A1 (zh) 2023-03-30
US20240391973A1 (en) 2024-11-28
EP4406965A4 (en) 2025-12-17
TWI858393B (zh) 2024-10-11
KR20240082364A (ko) 2024-06-10
JP2024534545A (ja) 2024-09-20
AU2022350407B2 (en) 2025-09-04
JP2026097838A (ja) 2026-06-16
AU2022350407A1 (en) 2024-05-02
CN118119635A (zh) 2024-05-31
JP7864826B2 (ja) 2026-05-25
MX2024003535A (es) 2024-05-07
PE20241994A1 (es) 2024-09-27
IL311643A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
CO2024004910A2 (es) Proteína mutante de interleucina-2 y fusión de la misma
CO2021012587A2 (es) Receptores de células t mage a4
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
AR126987A2 (es) Inmunoconjugados
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
AR119338A1 (es) Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8
CR20190594A (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
AR115389A1 (es) Anticuerpo antagonista de cd73
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112023005674A2 (pt) Construtos anti-cd93 e usos dos mesmos
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
MX2023007282A (es) Moleculas de union al antigeno especificas para la variante ror1.
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
CL2021001794A1 (es) Péptido, ácido nucleico, célula, composición farmacéutica, linfocito t activado, agente de unión aislado, y tcr, para su uso en inmunoterapia contra el cáncer; y métodos para producirlos (divisional de la solicitud no. 201600227)
BR112013006679A2 (pt) imunoglobulinas carreadoras e seus usos
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
CL2021002525A1 (es) Péptidos inmunoterapéuticos para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud n° 201801531)
PE20190436A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1
BR112018070600A2 (pt) receptores de células t
PE20232039A1 (es) Mutantes de proteina f de rsv
MX370356B (es) Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria.
MX385679B (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
DK1922334T3 (da) Tumorassocierede peptider, der binder til humant leukocyt antigen (HLA) klasse I eller II molekyler og dertil hørende anti-cancervaccine
CR20190319A (es) ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117)
BR112022024629A2 (pt) Construtos anti-cd93 e seus usos